Luis Rodriguez Carnero | Scientist
IQVIA
Luis is a Specifica-IQVIA Scientist who leads antibody discovery, affinity maturation and characterization campaigns using Specifica’s antibody discovery platform.
Luis holds a PhD in Biochemistry from the University of Sao Paulo, Brazil. During his PhD, he gained experience in small-peptide phage display and immunobiology. There, he used phage display to study the epitopes of neglected tropical diseases and find inhibitors of human transcription factors involved in malignancies.
While working with us, he’s been able to integrate into most steps of our antibody discovery process to increase the chances of successfully obtaining high-affinity antibodies.
Appearances:
Festival of Biologics Day 1 @ 14:40
The Specifica Generation 3 Antibody Library Platforms: High affinity drug-like antibodies and VHHs straight from in vitro selections.
Antibodies are vital therapeutics, but many fail due to poor developability traits, such as aggregation, poor stability and polyreactivity. The Specifica Generation 3 scFv Library Platform was designed to address this problem by embedding natural CDRs purged of sequence liabilities into highly developable clinical scaffolds, yielding highly diverse, high affinity (20% subnanomolar), developable (>80% lack biophysical liabilities), drug-like antibodies as potent or better than those from immune sources. This concept has now been extended to Fab and VHH libraries. This talk will discuss the in vitro selection of antibodies and VHHs from Specifica’s Generation3 library platform, as well as its application to affinity and developability improvement of antibodies generated from other platforms.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events